Preclinical research in GBM has revealed that combining an EGFR inhibitor with a mTOR inhibitor can modulate the TME by downregulating immunosuppressive chemokines and inhibiting tumour-promoting macrophage infiltration [98]. Here, MTOR is linked to glioblastoma.